Linezolid Amarox (Linezolid)

Linezolid is an oxazolidinone antibiotic used to treat serious Gram‑positive bacterial infections.

• Skin and soft tissue infections: effective against Staphylococcus aureus and other Gram‑positive organisms, reducing infection severity.
• Community‑acquired pneumonia: clears bacterial pathogens in lung tissue, improving respiratory function.
• Hospital‑acquired (nosocomial) pneumonia: targets resistant strains, aiding recovery.
• Methicillin‑resistant Staphylococcus aureus (MRSA) infections: eradicates MRSA, preventing spread and complications.

• Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing formation of the initiation complex and thereby blocking translation. This action halts bacterial growth and leads to bacteriostatic activity against susceptible Gram‑positive organisms, including resistant strains such as MRSA and VRE.

Linezolid may cause a range of adverse reactions, from mild to serious. Patients should be monitored for any new symptoms during therapy.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools that may be self‑limiting.
• Headache: transient cranial discomfort.
• Metallic taste: altered taste sensation.
• Insomnia: difficulty falling or staying asleep.
• Vomiting: occasional emesis.

Serious or Rare Side Effects

• Thrombocytopenia: significant drop in platelet count, increasing bleeding risk.
• Anemia: reduced red blood cell levels causing fatigue.
• Peripheral neuropathy: nerve damage leading to tingling or numbness.
• Serotonin syndrome: potentially life‑threatening reaction when combined with serotonergic agents.
• Severe hypotension: marked drop in blood pressure.
• Hepatic dysfunction: elevated liver enzymes indicating liver injury.

Before initiating Linezolid therapy, clinicians should assess patient‑specific risk factors and monitor relevant parameters.

• Pregnancy: Category C – use only if potential benefit justifies the risk to the fetus.
• Renal impairment: monitor renal function and adjust therapy as needed.
• Hepatic impairment: consider dose adjustment and monitor liver enzymes.
• Concomitant serotonergic drugs: avoid or closely monitor for serotonin syndrome.
• Blood counts: regularly assess hematologic parameters for thrombocytopenia or anemia.
• Store at ambient temperature: keep below 25°C, in the original pack, and protect from moisture.

Linezolid can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of severe serotonin syndrome.
• Selective serotonin reuptake inhibitors (SSRIs), SNRIs, tricyclic antidepressants: increase serotonin syndrome risk.
• Rifampin: induces metabolism, reducing linezolid plasma concentrations.
• Warfarin: may potentiate anticoagulant effect and increase bleeding risk.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): additive bleeding risk.
• Antacids containing aluminum or magnesium: may affect absorption.
• Cyclosporine: potential increase in linezolid toxicity.
• Digoxin: possible elevation of serum digoxin levels.
• Oral contraceptives: may experience reduced efficacy; consider alternative contraception.